Portfolio Development

NovaMedica is interested in developing the portfolio both through the development of own drugs and by attracting partner products in the area of treatment of diseases of the central nervous system (CNS) and rare diseases.

At the current stage, several NovaMedica developed RX-medicines for treatment CNS diseases are being prepared to launch the market, which will the existing portfolio.

In addition, cooperation with partner companies to bring drugs for the treatment of rare diseases to market is actively developing.

Our key partner in the field of rare diseases:

Founded in 2003, Marinus Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company located in Branford, Connecticut. Marinus is dedicated to the reformulation, development, and commercialization of Ganaxolone (Trade name Ztalmy^®). In Q1 2022 Ztalmy^® received an approval from US Food and Drug Administration (FDA).

ZTALMY^® is a prescription medicine used to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in people 2 years of age and older. It is not known if ZTALMY is safe and effective in children under 2 years of age. ZTALMY is a sugar-free cherry-flavored oral suspension suitable for ketogenic diets.

Clinical studies are ongoing on the use of the drug for the treatment of other similar diseases.

Please visit www.ztalmy.com for detailed information on the product.